Expert Recommendations for Administration of Blinatumomab and Looking to the Future
This webinar was presented by the Children’s Oncology Group (COG) Nursing Steering Committee on
February 12, 2025.
The intended audience for this webinar is primarily nurses, although allied health professionals will also find it beneficial. Attendees will gain insights into the AALL1731 study results and learn how nurses have effectively addressed challenges related to blinatumomab infusions in their institutions.
The webinar objectives are:
- Review AALL1731 study results
- Highlight nursing contributions to success of blinatumomab on COG clinical trials
- Brief review of qualitative results – perspective of caregivers
- Framework for improving healthcare experiences
- Perceived risks (to patient/family outcomes) with care delivery
- Consideration of hypogammaglobulinemia
- Sharing examples of delivery practices
- Rural populations
- 7-day bags
- Equipment challenges
- Prior authorization
Watch Expert Recommendations for Administration of Blinatumomab – COG Nursing Webinar Blinatumomab
If you collect Continuing Education Units, you can earn 1.5 hours by watching this presentation and using the QR code to access the evaluation.
Articles of Interest
- Bernhardt MB, Militano O, Honeyford L, Zupanec S. Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges. J Oncol Pharm Pract. 2021 Mar;27(2):376-388. doi: 10.1177/1078155220979047. Epub 2020 Dec 18. PMID: 33334253.
- Montgomery KE, Zupanec S, Yun C, Okada M, Kubaney H, Feehily E, Withycombe JS. A Quality Approach to Blinatumomab Delivery in Pediatric Oncology: A Children’s Oncology Group Study, 2024, J Pediatr Hematol Oncol Nurs (Epub 9 Sept 2024).
- Withycombe JS, Kubaney HR, Okada M, Yun CS, Gupta S, Bloom C, Parker V, Rau RE, Zupanec S. Delivery of Care for Pediatric Patients Receiving Blinatumomab: A Children’s Oncology Group Study. Cancer Nurs. 2024 Nov-Dec 01;47(6):451-459. doi: 10.1097/NCC.0000000000001309. Epub 2023 Nov 22. PMID: 38016041; PMCID: PMC11128477.